Bravis Ziekenhuis

Research site

The Netherlands Boerhaaveplein 1, 4624 VT Bergen Op Zoom, The Netherlands

3 trials recruiting
Vitiligo · Dermatitis atopic · Hidradenitis
Adults and children

About Specializations

Bravis Ziekenhuis in Bergen Op Zoom, The Netherlands specialises in clinical trials of conditions such as Vitiligo, Dermatitis atopic, Hidradenitis, Arteriosclerosis, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Boerhaaveplein 14624 VT Bergen Op ZoomThe Netherlands

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 10

More sites in Bergen Op Zoom The Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

13 clinical trials

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Povorcitinib
Sponsor:Incyte Corp.

Contact Research Centre

Human papilloma virus immunisation+1

Recruiting

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Registered drug

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Recruiting

Registered drugNo placebo

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amoxicillin Sodium
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Arteriosclerosis

Not recruiting

Investigating Lepodisiran for Reducing Cardiovascular Events in Adults with Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease or at Risk for a First Cardiovascular Event

Investigational

Investigating Lepodisiran for Reducing Cardiovascular Events in Adults with Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease or at Risk for a First Cardiovascular Event

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:LY3819469 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Hidradenitis

Not recruiting

Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

Registered drug

Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Secukinumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Chronic spontaneous urticaria

Not recruiting

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Barzolvolimab
Sponsor:Celldex Therapeutics Inc.

Contact Research Centre

Vitiligo

Not recruiting

Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment

Investigational

Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Vitiligo

Not recruiting

Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

Investigational

Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Povorcitinib
Sponsor:Incyte Corp.

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Incyte Corp.

Contact Research Centre

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Hydrocortisone
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites